About Vax Before Cancer
Vax-Before-Cancer is a research-based cancer information publisher that is ‘fact-checked’ by healthcare providers.
Over the past 20 years, innovative scientists have brought cancer-preventing vaccines and immunotherapies through the FDA’s rigorous clinical study process that are saving lives today.
And, there are many innovative vaccine candidates in clinical studies. The number of active compounds in development has grown to over 3,500, with the majority of those testing programs are focused on the T-cell-targeted immunomodulators.
Vax-Before-Cancer is owned and an affiliate of the Precision Vax, LLC network, including Precision Vaccinations and Vax-Before-Travel.
Researchers are testing vaccines and immunotherapies for several types of cancers:
Bladder cancer: Researchers are studying the effectiveness of a vaccine made from a virus modified to contain HER2 cells.
Brain tumors: Many studies test treatment vaccines aimed at certain molecules on the surface of brain tumor cells.
Breast cancer: Several studies test treatment vaccines for breast cancer, given alone or with other therapies.
Cervical cancer: The FDA has approved cervical cancer prevention vaccines.
Colorectal cancer: Researchers are creating treatment vaccines that encourage the body to attack cells with antigens thought to cause colorectal cancer.
Kidney cancer: Researchers are testing the use of several cancer vaccines to treat kidney cancer. They are also testing vaccines to prevent later-stage kidney cancer from recurring.
Leukemia: Studies are looking at treatment vaccines for various leukemia types, such as acute myeloid leukemia and chronic lymphocytic leukemia.
Lung cancer: Lung cancer treatment vaccines in clinical trials target antigens.
Melanoma: Researchers are testing destroying melanoma cells, and antigens in the vaccines encourage the immune system to destroy other melanoma cells in the body.
Pancreatic cancer: Researchers are working on several treatment vaccines designed to boost the immune system’s response to pancreatic cancer cells.
Prostate cancer: Sipuleucel-T is a vaccine doctors use to treat men with metastatic prostate cancer. Now researchers are studying if the vaccine can help men with less advanced prostate cancer.
Vax-Before-Cancer Mission Statement
Publish ‘fact-checked’ cancer information that empowers patients and healthcare providers to make informed vaccination decisions.
The weekly Vax-Before-Cancer newsletter is sent to your email address containing the latest information.
Vax-Before-Cancer publishes news based on research from universities, government agencies, pharmaceutical manufacturers, the CDC, and the WHO. These organizations do not influence the published content.
Our news-gathering team is independent of commercial or political interests. We do not accept gifts, including paid travel, to avoid any conflict of interest or appearance. We cite potential conflicts of interest on the same page as the published, relevant work.
If you have any questions contact, please contact our publisher at [email protected].
Vax-Before-Cancer Medical Advisory Team
The Medical Advisory Team works closely with our editorial team to ensure Vax-Before-Cancer published content is accurate, actionable, and understandable. We seek diverse voices in our reporting staff. If you have any questions, please contact Dr. Robert Carlson, [email protected].
Our news organization commits its best efforts to publish accurate information. We stand by the information we publish, and if it’s not correct, we will change it as quickly as possible.
We take many steps to ensure accuracy, such as:
- We investigate claims with skepticism, question assumptions, challenge conventional wisdom.
- We confirm information with subject-matter experts and seek to corroborate what sources tell us by talking with other informed people or consulting documents.
- We verify content, such as technical terms, stats, etc., against source documents or clarify who provides the information. We may share relevant components of a story with a primary source or an outside expert to verify them.
Inclusiveness is at the heart of thinking and acting as journalists. The complex issues we face as a society require respect for different viewpoints. Race, class, generation, gender, and geography all affect points of view. Reflecting these differences in our reporting leads to better, more nuanced stories and a better-informed community.
If our digital audiences cannot trust us to get the small things right, how can they trust us on the big things?
We welcome feedback from our readers regarding the information that we publish. Our news organization is committed to telling readers when an error has been made, the magnitude of the error, and the correct information, as quickly as possible. This commitment to transparency applies to small errors as well as large ones.
Please send any suggested changes to Vax-Before-Cancer's President, [email protected].
Terms of Service: By using our website, you signify your assent to these Terms and Conditions. If you do not agree to all of these Terms and Conditions of Use, please do not use this site. All information on this site is provided "as-is" for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health. The use of any information on this site is solely at your own risk. Vax-Before-Cancer may revise and update these Terms and Conditions at any time. Your continued usage of this website means you accept all changes.
Corrections: Vax-Before-Cancer is committed to making clarifications to its content when appropriate. We take prompt action to edit even minor errors like spelling, grammar, or stylistic changes. Because style changes do not change the content's meaning, those kinds of "style" changes will be updated on our site without notice.
Editorial: We are committed to publishing information on various immunization topics. We rely on you, our reader, to choose the most appropriate information for your needs. Information located on Vax-Before-Cancer should not be used as a substitute for professional healthcare advice.
Advertising: Vax-Before-Cancer accepts advertising from third parties ("Advertisers"), which may include third party banners, badges, contextual advertising, and content created or provided by an Advertiser (collectively referred to as "Advertisements" or "Advertising"). We have regularly sought sponsorships and advertisements from relevant commercial organizations, manufacturers, and other health leaders. These sponsorships, which are a form of advertising, enable us to provide you with our trusted content at no cost.
Vax-Before-Cancer Ownership Structure
Vax-Before-Cancer is owned by PrecisionVax, LLC, a woman-owned digital news network founded in 2016. Karen McClorey Hackett, the president of PrecisionVax, is committed to transparency in our ownership structure and revenue sources.
We produce our revenues from advertising. Our dominant advertiser is Google Adsense. Vax-Before-Cancer also has lead generation business agreements for discounts, clinical trials, diagnostic tests, and various healthcare providers for appointment requests.
Our editorial team has no relationship, nor communications, with any advertiser. If you have any questions, please contact [email protected].
Comments and Concerns
We believe that public feedback is not a one-way street. Instead, we are committed to engaging with you and taking action based on your suggestions, complaints, and other feedback. We will respond to your request asap. Please send an email to [email protected].
Karen Hackett, President